Frequently Asked Questions


At Okyanos, patients’ own adipose-derived stem and regenerative cells (ADRCs) are delivered both systemically and directly to areas of damage in the body. Among many other functions relevant to addressing different types of chronic conditions, ADRCs are known to be able to repair/replace damaged tissue, reduce in ammation and restore blood flow.

What conditions are treated at Okyanos with stem cell therapy?

Stem cell therapy can be beneficial from the earlier stages of a disease to the more aggressive and later stages. Okyanos treats patients with conditions such as heart failure, Parkinson’s, osteoarthritis and others who are seeking advanced therapies in conjunction with or beyond what is o ered by the currently available standard of care.

Why use stem cells from adipose (fat) tissue and not bone marrow?

Adipose contains up to 2,500 times more stem and regenerative cells than bone marrow, is more abundant, more quickly obtained and processed to a therapeutic dose using advanced lipoaspirate technology. Stem cell extraction from bone marrow is much more painful and can take weeks to process.

Why the Bahamas?

The Bahamas are a medically regulated jurisdiction, with a strong focus on safety coupled with a commitment to accelerating medical care and innovation for patients under careful oversight. Regenerative medicine and stem cell therapies remain highly unregulated throughout the world. For patients this translates to insufficient safety standards, zero facility inspection and no oversight of the resultant cell product(s) for purity and viability. Okyanos is proud to have been the first cell therapy facility to receive approval from the Bahamas National Stem Cell Ethics Committee (NSCEC) under legislation passed in 2013 which allows and regulates the use of patients’ own adult stem cells in the treatment of certain chronic conditions. In order to maintain accreditation, Okyanos has routine regulatory oversight and inspection to ensure safety.

What are the risks of the procedure?

The risks are minimal. Okyanos therapies have been shown to be safe and efficacious in scientific and/or medical literature for the conditions we treat, and there have been zero reports of cell-related adverse effects using a patient’s own adipose-derived stem and regenerative cells (ADRCs). Further, because these cells are autologous (a patient’s own) the risk of cell rejection is eliminated. For cardiac patients, the risk of bleeding is very low and the procedure is similar to having an angioplasty.